Pharmaceutical giant Elan has reported that total revenue for 2003 fell 34% on 2002's figure, to $746m (€578.59m).

TROUBLED pharmaceutical company Elan has completed the purchase of nearly all the so-called ‘poison put’ bonds that threatened its survival.

ELAN’s ongoing problems with the US Securities and Exchange Commission over its accounting procedures is the main inhibitor to investors after the company posted stronger than expected sales’ growth yesterday.

DRUGS company is Elan is set to see third-quarter sales halve when it reports results later this week.

ELAN will make another attempt at developing a treatment for Alzheimer’s disease a year after a previous drug had to be cancelled.

A MIXED day for Irish equities saw the ISEQ index slip 38.18 points to 4356.27.